Sorry, you need to enable JavaScript to visit this website.
Skip to main content

KAPRUVIA® IS A TARGETED, FIRST-IN-CLASS AND THE ONLY LICENSED TREATMENT FOR CKD-ASSOCIATED PRURITUS IN US & EU*1

By activating kappa-opioid receptors (KORs), KAPRUVIA® addresses two underlying mechanisms of chronic kidney disease-associated pruritus (CKD-aP).2-4

  • KAPRUVIA® is a small peptide, with a hydrophilic structure which restricts its diffusions across the blood-brain barrier, limiting access to KORs in the CNS1
  • KAPRUVIA® is highly selective towards KORs (>30,000 fold over mu-opioid receptors (MORs))2
Test

KAPRUVIA® MODE OF ACTION

CKD, chronic kidney disease; CKD-associated Pruritus, chronic kidney disease-associated pruritus; CNS, central nervous system; KORs, kappa-opioid
receptors; MORs, mu-opioid receptors.

 

*In China, Korea and Japan further products are available and indicated for the treatment of CKD-associated Pruritus.

References:

  1. Lipman ZM, Yosipovitch G. Expert Opin. Pharmacother. 2020;1–7.
  2. Albert-Vartanian A, et al. Journal of Clinical Pharmacy and Therapeutics. 2016;41:371–382.
  3. KAPRUVIA® Summary of Product Characteristics, 2022.
  4. Verduzco HA & Shirazian S. Kidney Int Re. 2020;5:1387–1402.
  5. Beck T C, et al. Pharmaceuticals. 2019;12:95.

Disclaimer: This is an international website for Kapruvia and is intended for health care professionals outside the US. If you are a US resident, please go to korsuva.com/hcp. The information on this site is not country-specific and may contain information that may not be relevant in the country in which you are located.